Poolbeg identifies strategic drug targets for treatment of RSV

The culture of collaboration in the Pacific Northwest, the impact of AI on biopharma, and the shape of new business models driven by AI were all topics at a panel discussion Wednesday in Seattle at the

Poolbeg Pharma is very pleased to see the approval of multiple CAR T cell therapies for earlier treatment of multiple myeloma. As an oral preventative therapy for CRS, POLB 001 has the potential to enable broader,

On April 8, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to Poolbeg Pharma Limited, a UK-based company. The license concerns, “Adoptive

Phase 2 Ready orally administered p38 MAP Kinase inhibitor – a preventative therapy targeting an addressable market of more than $10 billion. POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer

Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application. This AIM-traded firm said the development pertained to POLB 001, a potent

Poolbeg Pharma has announced that it has received a Notice of Allowance from the US Patent Office in relation to its Immunomodulator II patent application. A Notice of Allowance is a precursor to the expected formal grant

February may be the shortest month, but we got an extra day this year and that left plenty of time for personnel announcements in the pharma world. Read on for a roundup of the month’s hiring

As the global obesity epidemic continues to escalate, the development of effective obesity management solutions has become a front and centre topic in the life sciences sector. With over 650 million adults worldwide classified as obese,

To mark upcoming Rare Disease Day, pharmaphorum asked a panel of experts to give their thoughts on the opportunities and challenges facing developers of rare disease therapies in 2024. The panel comprised: Jean-Philippe Combal, CEO of

U.K.-based Poolbeg Pharma is taking a different approach with its POLB 001, a small molecule immunomodulator that has already shown promise in a lipopolysaccharide (LPS) human challenge trial. A human challenge trial is a type of clinical

Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery. The AIM-traded firm

Cathal Friel, co-founder, substantial shareholder, and currently non-executive chairman of London-listed Poolbeg Pharma (AIM: POLB), is assuming the role of executive chairman at the company effective immediately. As executive chair he will continue to work closely

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Businessman Cathal Friel has become executive chairman of Poolbeg Pharma, the same job he had at Open Orphan (now hVivo) as that firm was developed. Mr Friel, a co-founder and substantial shareholder, was already non-executive chairman

Poolbeg Pharma, a biopharmaceutical company specialising in the development and commercialisation of medicines targeting rare and orphan diseases, today announces that independent research conducted on its behalf confirms a >$10 billion market opportunity for POLB 001 in Cancer